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Considerable variation in grading systems used to rate the
strength of guideline recommendations and the quality of
the supporting evidence in Nephrology highlights the need
for a uniform, internationally accepted, rigorous system. In
2004, Kidney Disease: Improving Global Outcomes (KDIGO)
commissioned a methods expert group to recommend an
approach for grading in future nephrology guidelines. This
position statement by KDIGO recommends adopting the
Grades of Recommendation Assessment, Development, and
Evaluation (GRADE) approach for the grading of evidence
and guidelines on interventions. The GRADE approach
appraises systematic reviews of the benefits and harms of an
intervention to determine its net health benefit. The system
considers the design, quality, and quantity of studies as well
as the consistency and directness of findings when grading
the quality of evidence. The strength of the recommendation
builds on the quality of the evidence and additional
considerations including costs. Adaptations of the GRADE
approach are presented to address some issues pertinent to
the field of nephrology, including (1) the need to extrapolate
from studies performed predominantly in patients without
kidney disease, and (2) the need to use qualitative summaries
of effects when it is not feasible to quantitatively summarize
them. Further refinement of the system will be required for
grading of evidence on questions other than those related to
intervention effects, such as diagnostic accuracy and prognosis.
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Because of the marked increase in the number of available
treatments and diagnostic techniques, and the exponential
increase in the number of related publications, it is difficult
for the busy practitioner to keep abreast of the accruing
evidence for best practice. As a result, most specialties have
invested considerable effort and resources to develop clinical
practice guidelines (CPGs) that are based on systematic
reviews and critical appraisal of primary research studies.
CPGs make specific recommendations to assist practitioner
and patient decisions about appropriate health care in
specific clinical conditions or settings.1 The grading of
evidence and guideline recommendations is an integral part
of CPG development, and a principal determinant of their
adoption and implementation. A standardized grading
system facilitates communication and allows for the compar-
ison of recommendations made by different groups of
experts. Unfortunately, there is considerable variation in the
grading systems used in current nephrology guidelines.
The Kidney Disease: Improving Global Outcomes (KDI-
GO) is an independently incorporated non-profit foundation
governed by an international board of directors with the
stated mission to ‘improve the care and outcomes of patients
with kidney disease worldwide, through promoting coordi-
nation, collaboration, and integration of initiatives to
develop and implement clinical practice guidelines’.2 This
provides a unique opportunity to develop a consistent
approach and nomenclature for grading of evidence reports
and guideline recommendations in nephrology. In 2004, the
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KDIGO Board of Directors commissioned an evidence-rating
group (ERG) composed of individuals with expertise in
nephrology, guideline development, and systematic review of
literature to develop a uniform grading system for use in
developing guidelines for patients with kidney disease. The
ERG met for 2 days in St Louis, MO, USA in November 2004
to (1) review the state of the art of evidence and guideline
grading; (2) develop consensus on a grading approach for use
in future guidelines developed in the domain of kidney
disease that would reasonably balance simplicity with
complexity and satisfy the criteria outlined in Table 1; and
(3) identify unresolved issues that require future action. Its
subsequent deliberations were conducted by conference calls
and e-mails. The recommendations made by the ERG were
then reviewed and adopted by the KDIGO Board of Directors
as a position statement on guideline development. The
position statement has also been reviewed by representatives
for Caring for Australasians with Renal Impairment, United
Kingdom Renal Association, European Best Practice Guide-
lines, Canadian Society of Nephrology, and Kidney Disease
Outcomes Quality Initiative. This publication describes the
background, process, and considerations that led to the
recommendations.
GRADING IN GUIDELINE DEVELOPMENT
Transparent appraisal of evidence can only be undertaken in
the context of a structured evidence review process. This
entails identification of important clinical questions and
relevant outcomes, their deconstruction into well-formulated
and searchable questions, performance of systematic reviews
that critically appraise the quality of available individual
studies and bodies of evidence, and application of the results
to the clinical context. When an evidence review is being
conducted in order to develop CPGs, it is essential that the
guideline work group have expertise in the relevant clinical
areas as well as in methods of systematic review and critical
appraisal of the literature. A full understanding of the concepts
employed in the grading of evidence and recommendations
from the outset is important to direct the evidence review to
studies that examine outcomes of clinical relevance to patients
and to synthesize the evidence in a way that will allow the
application of a structured grading approach.
The issues related to grading evidence for CPGs are
complex.3 Several approaches and systems for grading
evidence and guideline recommendations are now used.4,5
Grading systems that are entirely based on study design are
rather simplistic. They do not consider the methodological
quality of the studies, consistency of effects across studies,
quantity of research data, or its applicability to the
population of interest. On the other hand, systems with a
more structured approach to grading the quality of evidence
that go beyond type of study design tend to be complex, may
be more difficult to use, and introduce an element of
subjectivity. Applying different grading systems to the same
body of evidence may lead to markedly different conclu-
sions.6 Use of the same approach applied to the same
evidence by different users may also yield different grades.7
This variability in grading may be reduced, albeit not
eliminated, by using a structured and explicit approach to
grading.7,8
Most rating systems are particularly suited for grading the
evidence from randomized clinical trials (RCTs). Although
the RCT remains the gold standard study design to evaluate
efficacy of an intervention, questions regarding diagnosis,
prognosis, or harms may be best evaluated with other types
of study design.9,10 Some of the issues facing developers of
nephrology guidelines are shown in Table 2.11–13 These
particularities of the evidence need to be considered when
evaluating the suitability of a system for grading evidence on
kidney disease.
THE GRADE APPROACH
Overview of the GRADE approach
The ERG reviewed grading systems used for guideline
development by both nephrology and non-nephrology
organizations,5 including that developed by the ‘GRADE
(Grades of Recommendation Assessment, Development and
Evaluation) Working Group’.14 The GRADE Working Group
is composed of international experts in the field of evidence-
based medicine and guideline development convened to
overcome the shortcomings of existing grading systems. The
GRADE approach has several strengths: (1) it provides a
structured, explicit approach to grading the quality of
evidence for questions regarding interventions; (2) it requires
graders to explicitly identify how the grades are derived and
where judgment is involved; (3) it has been piloted on a
number of evidence profiles;7 and (4) it has been adopted by
other organizations.15,16
The GRADE system assigns separate grades for the quality
of evidence and for the strength of recommendations. It is
suitable for questions that address the efficacy of clinical
interventions and incorporates summary effect estimates
from meta-analyses. The quality of the evidence is defined as
the extent to which ‘one can be confident that an estimate of
effect or association can be correct’. This is based on the
likelihood that further targeted research would not change
confidence in the estimate. The strength of recommendation
indicates ‘the extent of the grader’s confidence that adherence
to the recommendation will do more good than harm’.
Table 3 shows the sequential process recommended by
GRADE for guideline development. Steps 1–3 describe the
Table 1 | Specifications for an ideal system for grading
evidence and recommendations related to nephrology
Supports the user in making well-informed decisions
Simple and easily understood
Explicit and transparent system of grading
Comprehensive evaluation of quality of evidence, not only study design
Incorporates evaluation of all important clinical outcomes
Explicit consideration of balance between benefits and harms
Applicable when grading evidence in the nephrology domain
Consistent with grading systems in other specialities
Applicable to a range of clinical questions and types of evidence
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process that is followed for conducting the systematic reviews
and for tabulating data in evidence profiles. Evidence profiles
provide a summary of the effects for each important outcome
and record the decision making for each step of grading and
synthesis. Steps 4–7 describe how to grade the quality of the
evidence and to assess the net health benefit. Steps 8 and 9
describe how to determine whether to issue a recommenda-
tion and of what strength.
Grading the quality of evidence for each important outcome
In Step 4, the quality of evidence for each important
clinical outcome is graded (Table 4). This entails assigning a
grade for the quality of the aggregate of studies that look
at the effect of an intervention on one type of outcome.
The level for the quality of the evidence can be ‘high’,
‘moderate’, ‘low’, or ‘very low’. For a question of intervention,
the quality grade for an aggregate of RCTs would start
of at the entry level of ‘high’; a collection of observational
studies would start at the entry level of ‘low’ and
evidence from studies of other designs (for example,
from case–control studies) at ‘very low’. Subsequently, the
level for the quality of evidence for a particular outcome is
reduced or downgraded, if there are limitations to the
methodological quality of the studies, inconsistencies be-
tween studies, limitations of the directness of the evidence
(i.e. the evidence does not apply directly to the populations,
interventions, or outcomes of interest), imprecise or
sparse data, or a high probability of reporting bias. On the
other hand, the level of evidence of observational studies
would be raised or upgraded, if there is evidence of a strong or
very strong association between the intervention and the
outcome, a dose–response gradient, or if unmeasured
confounders would have reduced the effectiveness of an
intervention. The final grade for the quality of the evidence
cannot move higher than to ‘high’ level, or lower than to
‘very low’ level.
Table 2 | Characteristics of CKD and CKD practice that need to be considered in grading
Particularities about CKD Grading needs to explicitly consider
Clinically silent disease Laboratory outcomes (halving of GFR or doubling serum creatinine)
Long, chronic course of the disease over decades Surrogate outcomes (proteinuria, LVH)
Clinical outcomes of interest are
Progression to kidney failure
Concurrent development or progression of CVD
Impairment of QOL
Development or progression of complications of CKD
Multiple outcomes, competing risks
Relatively small number of high-quality studies examining critical
clinical outcomes in populations with CKD
Extrapolation of evidence from RCTs in non-target populations
Large RCTs of ‘non-target’ populations include subpopulations
with unrecognized CKD, for example, individuals with albuminuria
or moderately reduced GFR
Extrapolation of evidence from studies that did not separate
CKD patients into a subgroup
Lack of RCTs that concurrently and definitively examine all important
clinical outcomes and harms
Decision analyses that aim to determine tradeoffs between harms
and benefits, in particular quantity and quality of life from dialysis
and kidney transplantation
Variations in health policy and payment for dialysis or kidney
transplantation
Patient and society perspectives affected by different structures
and payment systems
CKD, chronic kidney disease; CVD, cardiovascular disease; GFR, glomerular filtration rate; LVH, left ventricular hypertrophy; RCT, randomized controlled trial; QOL, quality
of life.
Table 3 | Sequential steps for developing guidelines according to GRADE14
Step 1: Establishing the process. Prioritization of problems and definition of key questions to be addressed. Selection of guideline group, agreement
on group processes.
Step 2: Systematic review. Formulation of good questions, identification of important clinical outcomes including harms. Identification, extraction,
and tabulation of best available evidence or appraisal of existing systematic reviews. Assessment of the effects on relevant outcomes.
Step 3: Preparation of evidence profiles: for each patient subgroup, profiles are prepared based on the results of systematic reviews which tabulate the
summary of findings for each relevant outcome and appraise design and methodological quality of studies, consistency, and directness of the
evidence as well as other modifying factors.
Step 4: Grading the quality of evidence for each clinically important outcome. Based on criteria in Table 4.
Step 5: Weighting relative importance of each outcome: ranking of importance of outcomes as ‘critical’, or ‘important, but not critical’.
Step 6: Grading the overall quality of evidence across all important outcomes. Consideration of the quality of the evidence for each important outcome
in view of the relative importance of each outcome.
Step 7: Balance of benefits and harms. Assessment of the net health benefit across all important clinical outcomes.
Step 8: Review of other considerations, including costs, in addition to net health benefit and quality of the evidence.
Step 9: Formulation of a guideline recommendation and grading the strength of the recommendation based on the level of confidence, that adherence
will do more good than harm. See Table 5.
GRADE, Grades of Recommendation Assessment, Development, and Evaluation.
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The GRADE Working Group argues that the
review of harms of an intervention may require the
inclusion of studies that are not RCTs into the systematic
review. RCTs may be useful for ascertaining short-term
harms occurring at a relatively high frequency. This may need
to be supplemented with data from longitudinal cohort
studies, registries, case reports, and post-marketing surveil-
lance to capture rare or delayed adverse events. Currently, the
selection of data sources on harms may be somewhat
arbitrary. Going forward, applying standards for reporting
evidence on harms will improve the ability to systematically
identify studies, that report harms, as well as the quality of
this data.17
Weighting the importance of each outcome and grading the
overall quality of the evidence
In Step 5 (Table 3), each outcome is ranked as ‘critical’ or
‘important, but not critical’ and in Step 6, the overall quality
of the evidence is assessed across all critical and important
outcomes, taking into account the relative importance of
each outcome. This involves complex and potentially
subjective decision making, which weighs the quality of
evidence for each clinical outcome by its relative importance.
According to the GRADE approach, the grade for the overall
quality of evidence is based on the grade for the outcome
with the lowest quality of evidence, if the outcome is crucial
to making a decision. This rule applied to an example in
individuals with chronic kidney disease (CKD) means that
the impact on critically important outcomes such as
cardiovascular disease (CVD) events and mortality need to
be considered together with outcomes from kidney disease
progression or harms, when treatment to a blood pressure
target is evaluated. The quality of the overall evidence for a
specific blood pressure target would be graded as moderate, if
the quality of evidence for CVD mortality is moderate, even
when the quality of evidence for kidney disease progression
and proteinuria is strong.
Determination of net health benefit
In Step 7 (Table 3), the net health benefit is determined based
on the anticipated balance of benefits and harms across all
clinically important outcomes. This step may again require
complex decision making to add up the benefits and risks for
different outcomes. The assessment of net medical benefit
can be affected by judgments, for example, when attaching a
relative value to one outcome versus another. The assessment
of net health benefit is summarized in one of the following
statements: (1) there is net benefit from the intervention
when the benefits outweigh the harms, (2) there is no net
benefit, (3) there are tradeoffs between benefits and harms
when harms do not altogether offset benefits, but require
consideration in decision making, or (4) there is remaining
uncertainty as to the net benefit. The GRADE approach
recommends that the net health benefit be determined before
costs are considered.
Grading the strength of a recommendation
High or moderate quality of evidence supports the develop-
ment of a guideline recommendations when this is also
supported by other considerations such as the baseline risk of
the population of interest, features of particular practice
settings, availability of the service, accessibility to care and
costs (Step 8, Table 3). If an evidence-based guideline
recommendation is issued, its strength is graded (Step 9,
Table 3). As shown in Table 5, the strength of a
recommendation is either ‘strong’ (i.e. ‘We recommend you
do it.’ for a positive recommendation or ‘We recommend you
do not do it.’ for a negative recommendations) or ‘weak’ (‘We
Table 4 | GRADE System for grading quality of evidence
Step 1: Starting grade for quality
of evidence based on study design Step 2: Reduce grade Step 3: Raise grade
Final grade for quality of evidence
and definition
Randomized trials=high Study quality
-1 level if serious limitations
-2 levels if very serious limitations
Strength of association High=Further research is unlikely to
change confidence in the estimate
of the effect
Observational study=low Consistency
-1 level if important inconsistency
+1 level if strong*, no plausible
confounders
Moderate=Further research is likely
to have an important impact on
confidence in the estimate of effect
and may change the estimate
Any other evidence=very low Directness
-1 level if some uncertainty
-2 levels if major uncertainty
-1 level if sparse or imprecise data
-1 level if high probability of
reporting bias
+2 levels if very strong**, no major
threats to validity
+1 level if evidence of a dose
response gradient
+1 level if all residual plausible
confounders would have reduced
the observed effect
Low=Further research is very likely
to have an important impact on
confidence in the estimate and may
change the estimate
Very Low=Any estimate of effect is
very uncertain
GRADE, Grades of Recommendation Assessment, Development, and Evaluation.
Modified from GRADE Working Group14 and Kunz and Farquhar.24
*Strong evidence of association is defined as ‘significant relative risk of 42 (o0.5)’ based on consistent evidence from two or more observational studies, with no plausible
confounders.
**Very strong evidence of association is defined as ‘significant relative risk of 45 (o0.2)’ based on direct evidence with no major threats to validity.
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suggest you do it.’ or ‘We suggest you do not do it.’).16 A
guideline development group may state that a guideline
recommendation cannot be issued when the net health effect
is unclear (e.g., when the quality of the evidence is
insufficient or when there are tradeoffs between important
clinical outcomes), or when there is low incremental benefit
for high incremental cost. Another alternative proposed by
the ERG is the issuing of a consensus-based statement.
MODIFICATION OF THE GRADE APPROACH
The evidence base in CKD has specific characteristics that
impact on the quality and quantity of available primary
studies and systematic reviews (Table 2). Therefore, certain
modifications to the GRADE approach are recommended in
the following areas.
1. Extrapolation of evidence from non-CKD to CKD
populations
The number of patients with CKD that have been included in
RCTs of interventions designed to improve cardiovascular
outcomes or all-cause mortality is limited. Yet, individuals
with CKD are more likely to die of CVD than of
kidney failure.18 Going forward, interventions that
aim at reducing CVD outcomes and mortality have to be
studied in individuals with CKD to generate high-quality
evidence that is directly applicable to this patient population.
Meanwhile, when developing CKD guidelines, there may
be a need to incorporate evidence extrapolated from RCTs
that did not include CKD patients, or did not separate
CKD patients into a subgroup. In such instances,
it is recommended to follow the method developed
by the National Kidney Foundation Taskforce on CVD
in Chronic Renal Disease, which provides criteria
for the extrapolation of evidence from RCTs on CVD
interventions in the general population to populations
with CKD.19 The following questions help determine
whether the evidence from the non-CKD population is
applicable to a CKD population of interest and how
directly it may apply when grading the directness of the
evidence.
a. Are the mechanisms and expression of the disease in the
CKD population similar to those observed in the non-
CKD population? Specifically, are the features of the
disease, the relationship of outcomes to risk factors, the
mechanism of treating the risk factor (e.g. antihyper-
tensive medication rather than ultrafiltration to reduce
blood pressure), and the responsiveness of the risk factor
to treatment similar in the CKD and the non-CKD
population?
b. Are the interventions in the CKD population as
safe, or nearly so, as in the non-CKD population? For
example, might the therapy of interest have additional
adverse effects in CKD, such as toxicity to the kidneys or
other adverse effects as a result of altered pharmaco-
kinetics?
c. Is the duration of intervention required to improve
outcomes in the non-CKD population within the life
expectancy of the CKD population? For example, it is
important to determine whether the target population
with CKD is likely to survive long enough to benefit from
a therapy that takes a long time to lower risk for CVD.
The estimated average life expectancy is 4.3 years in 60-
to 64-year-old patients treated by chronic dialysis, with
a range of 3.9–5.9 years depending on gender and race.20
Table 5 | Strength of guideline recommendations, consensus-based statements, and linkage to quality of evidence
Recommendation
or statement
Description in
GRADE approach Prerequisite Assumption Implication
Strong guideline
recommendation
We recommend (should) The quality of the evidence
is ‘high’ and other
considerations support a
strong recommendation
Most well-informed individuals
will make the same choice14
The expectation is that the
recommendation will be
followed, unless there are
compelling reasons to deviate
from the recommendation in
an individual. A strong
recommendation may form the
basis for a clinical performance
measure
Weak guideline
recommendation
We suggest (might) The quality of the evidence
is ‘high’ or ‘moderate’,
and other considerations
support a ‘weak’
recommendation
A majority of well-informed
individuals will make this
choice, but a substantial
minority may not14
The expectation is that
consideration should be given
to follow the recommendation
Consensus-based
statement
Not applicable The quality of the evidence
is ‘low’, ‘very low’, or absent.
This is a consensus based on
expert opinion, supported
in the public review of the
statement
The expectation is that
consideration should be given
to follow the statement
GRADE, Grades of Recommendation Assessment, Development, and Evaluation.
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If studies of CVD in the general population show that it
takes 2–5 years to realize a benefit from certain
interventions, it may be assumed that this benefit to
the general population would translate to benefit in
dialysis patients.
Evidence extrapolated from a non-CKD population to a
CKD population may need to be downgraded to account for
the lack of proven efficacy in the CKD population.
2. Qualitative summary of results in evidence profiles
The GRADE approach builds on evidence profiles with
quantitative effect summaries from meta-analyses. Quantita-
tive estimates of summary effects may be provided by existing
high-quality and up-to-date meta-analyses or generated by
new meta-analyses that are conducted at the time of
guideline development. When quantitative effect summaries
are not available, guidelines may have to rely on systematic
reviews with descriptive, qualitative summaries. This allows
for guideline development to proceed even when there are no
adequate existing meta-analyses and when it is not feasible to
conduct them at the time of guideline development. Still, lack
of quantitative effect summaries may impact on the certainty
with which the effect for each outcome and the balance of
benefits and harms can be assessed.
3. Definition of ‘serious’ or ‘very serious limitation to study
quality’
The GRADE system suggests using explicit criteria for
grading the quality of studies but does not provide
definitions for ‘serious’ or ‘very serious limitations’. Table 6
shows an example of a three-tiered grading system, which has
been used in Kidney Disease Outcomes Quality Initiative
guidelines for assessing study quality independently of
study design. Accordingly, ‘no limitations’ would apply to
studies with the highest quality grade (A), ‘serious limita-
tions’ would apply to studies with the middle grade (B), and
‘very serious limitations’ would apply to studies with the
lowest grade (C).
4. Definition of ‘imprecise or sparse’ data
The GRADE system specifies ‘imprecise or sparse data’ as an
additional criterion that can lower the quality of the evidence
by one level (Table 4, Step 2). For the purpose of nephrology
guidelines, it is recommended, albeit arbitrarily, that data not
be considered to be sparse for an outcome of interest, if there
is one adequately powered, relevant RCT with over 1000
patients, or if there are two or more high-quality, adequately
powered RCTs with consistent findings.
5. Reporting bias
Another additional criterion specified in the GRADE
approach is that of reporting bias. Reporting bias may occur
through many mechanisms. It may occur when a study is not
published because of early termination, unfavorable results or
other reasons (publication bias), when the results of a study
are published repeatedly without acknowledgement (duplica-
tion bias), or when results are reported selectively (outcomes
reporting bias).21 Different methods for assessing publication
bias have been promoted and criticized.22 At present, it is
difficult to conduct a formal assessment of potential
publication bias. The development of clinical trial registries
and initiatives to register trial protocols will improve the
ability to assess this type of bias. It is reasonable to expect
guideline developers to review the funding sources of studies
included in the systematic review and to consider the
possibility of bias introduced by single party or commercial
sponsorship.
6. Strength of recommendations, negative recommendations
and consensus based statements
It is recommended that the strength of a guideline
recommendation be described in parentheses following the
statement, that is, ‘Strong’, ‘Weak’, or ‘Consensus based’.
Negative guideline recommendations can be used to
discourage ineffective or harmful health practices. Similar
to positive recommendations, negative recommendations
should be supported by evidence of high or moderate quality.
For negative recommendations, the evidence should show a
lack of net benefit, either with absence of a clinically
meaningful benefit or with an unfavorable benefit–harms
ratio.
When the available evidence is of inadequate quality,
opinions may vary, making it difficult to issue evidence-based
CPGs. If a work group has a strong opinion on a topic with
evidence of low or very low quality, the work group may
decide to issue a statement based on consensus, rather than
evidence. Consensus-based statements should be clearly
labelled to distinguish them from evidence-based guideline
recommendations. This will help prevent consensus-based
statements from being used out of context or without
their ‘qualifier’. In addition, it is very important that
Table 6 | System used in KDOQI Guidelines for grading study quality
A Least bias; results are valid. A study that mostly adheres to the commonly held concepts of high quality, including the following: a formal study; clear
description of the population and setting; clear description of an appropriate reference standard; proper measurement techniques; appropriate
statistical and analytic methods; no reporting errors; and no obvious bias. Not a retrospective study or case series.
B Susceptible to some bias, but not sufficient to invalidate the results. A study that does not meet all the criteria in category above. It has some
deficiencies but none likely to cause major bias.
C Significant bias that may invalidate the results. A study with serious errors in design or reporting. A study with large amounts of missing information
or discrepancies in reporting.
KDOQI, Kidney Disease Outcomes Quality Initiative.
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consensus-based statements, together with the evidence and
rationale on which they were based, undergo pre-publication
review by pertinent organizations, providers, patients, and
other stakeholders.
7. Research recommendations
Recommendations for future research should be an integral
part of systematic evidence review and guideline develop-
ment. In particular, suggestions for future research should be
provided to highlight the gaps in clinical information and
suggest how these gaps could be filled. This is especially
valuable for consensus-based statements, which lack strong
evidence.
8. Global guidelines and local adoption
The GRADE Working Group recommends that the net health
benefit to the patient should be determined and the quality of
the supporting evidence should be graded before costs are
considered. This appears to be appropriate for global
guideline development, as costs and incremental benefit for
an individual or a society may vary considerably in different
contexts. Also, the net health benefit of an intervention may
vary depending on patient characteristics, care settings, value
judgments, or other considerations that vary by region. These
important regional variables would be impossible to
incorporate in core global guidelines. It is in the adoption
of global guidelines that the applicability and strength of each
guideline have to be reviewed by a group of local experts and
assessed for the specific context.15 For some recommenda-
tions, the strength may change based on local resources and
priorities. For others, the content of the actual recommenda-
tion may change. In such cases, local guideline development
experts and implementation groups can review graded
evidence profiles and follow the GRADE approach to develop
recommendations that take local considerations into account.
The strength or content of recommendations issued by local
expert groups, even though they are based on a common
body of evidence, may thus differ for a variety of justifiable
reasons. This emphasizes the importance of detailing each
step in the grading process for the development of global
guidelines.
TESTING THE UTILITY OF THE MODIFIED GRADE APPROACH
The proposed modified GRADE approach was piloted in
Kidney Disease Outcomes Quality Initiative guideline
development work groups. Examples of evidence profiles
and how they supported the deliberations in guideline
development and grading are provided in the 2006 Kidney
Disease Outcomes Quality Initiative Anemia in CKD Guide-
lines.23
CONCLUSION
An explicit process for systematic evidence review forms the
basis for structured grading of the quality of evidence and the
strength of recommendations that are built on that evidence.
There is a need to have an internationally accepted, standard
approach to grading evidence and recommendations for
future nephrology guidelines. The proposed adoption of the
GRADE approach for grading evidence on interventions with
some modifications fills that gap. Future scientific inquiry
and evaluation needs to assess the value and role of this
approach for the development of global guidelines in
nephrology. Ongoing efforts for improving systems for
evidence grading, for questions on treatment efficacy and
other types of questions, should be monitored to determine
their suitability for use in the development of nephrology
guidelines.
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